Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials.
about
B-cell survival factors in autoimmune rheumatic disordersBelimumab in systemic lupus erythematosus: a perspective reviewPatient-reported outcomes in lupus clinical trials with biologics.Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot studyBelimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness.The lupus impact tracker is responsive to changes in clinical activity measured by the systemic lupus erythematosus responder index.International multi-center evaluation of a novel chemiluminescence assay for the detection of anti-dsDNA antibodies.Comparison of the Sensitivity to Change of the 36-Item Short Form Health Survey and the Lupus Quality of Life Measure Using Various Definitions of Minimum Clinically Important Differences in Patients With Active Systemic Lupus Erythematosus.Response to: 'belimumab and the measurement of fatigue' by Mazzoni.B Cell-Based Treatments in SLE: Past Experience and Current Directions.Systemic lupus erythematosus.Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod.Patient-reported outcome measures for use in clinical trials of SLE: a review
P2860
Q26796484-85CB5597-6113-4CF4-AA2B-53A916A1B1FEQ26796486-09448986-863C-4C0F-A1D9-CD97870865AEQ30391564-D0AFFADA-D037-4D62-B0AF-576C3F9078EEQ37464041-35402C1C-E9B8-4307-83B1-A1F959D284D9Q37698526-A08BD27A-7C79-49F1-83D8-6925D1EC6B3EQ39429702-A51ED992-0233-46F3-BB7B-3088896562FDQ39716610-E8B7F9C7-3A4B-4759-BA40-5CD30ECFCC2AQ46160179-74F0E5B4-D90C-48CE-BA7E-124D8FB55F5DQ46254756-3B514540-99DF-4F56-9E9C-CB9C93ECE042Q47660691-6A92D27D-0DF8-44CB-BFE9-DD85E961B01FQ50848358-BCB3771D-EE4D-45D6-AAD3-4A8A9BBB0880Q52862110-6D2E7C68-D998-470C-A47E-10351042D952Q58729793-F94605BF-F539-4660-A4FA-203544C349AF
P2860
Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Clinical, laboratory and healt ...... the phase 3 belimumab trials.
@ast
Clinical, laboratory and healt ...... the phase 3 belimumab trials.
@en
Clinical, laboratory and healt ...... the phase 3 belimumab trials.
@nl
type
label
Clinical, laboratory and healt ...... the phase 3 belimumab trials.
@ast
Clinical, laboratory and healt ...... the phase 3 belimumab trials.
@en
Clinical, laboratory and healt ...... the phase 3 belimumab trials.
@nl
prefLabel
Clinical, laboratory and healt ...... the phase 3 belimumab trials.
@ast
Clinical, laboratory and healt ...... the phase 3 belimumab trials.
@en
Clinical, laboratory and healt ...... the phase 3 belimumab trials.
@nl
P2093
P2860
P1476
Clinical, laboratory and healt ...... the phase 3 belimumab trials.
@en
P2093
BLISS-52 and BLISS-76 Study Groups
Richard Furie
Vibeke Strand
William W Freimuth
Z John Zhong
P2860
P304
P356
10.1136/LUPUS-2014-000031
P577
2014-06-26T00:00:00Z